Zhang et al. [138] found that MET amplification in lung cancer patients attenuated the tumor response to immunotherapy by inhibiting the STING levels and reducing the antitumor T-cell infiltration, suggesting that combining MET inhibitors with an immune checkpoint blockade could help overcome resistance. This evidence concerns the gene MET and lung carcinoma.